New studies link cannabis use to memory and brain changes

Heavy lifetime cannabis use was linked to lower brain activation during a working-memory task in 1,003 young adults, adding a specific new clue to a debate often flattened into yes-or-no claims. The strongest signal came from memory-related brain activity, not from broad measures of intelligence or general health, and the pattern held even after researchers excluded people with recent cannabis use.

The January 2025 study in JAMA Network Open defined heavy lifetime use as more than 1,000 uses and drew on MRI scans, urine toxicology and cannabis-use histories from the Human Connectome Project. Researchers looked at adults ages 22 to 36 and found that the association with lower activation was most pronounced during working-memory tasks. The result did not appear to be explained by age at first use, alcohol use, nicotine use or demographic factors, which makes it one of the more substantial pieces of brain-imaging evidence now entering the conversation.

What makes the newest reporting more surprising is that age itself may be part of the story. A health report published June 18, 2026, framed the question this way: cannabis used in adolescence, midlife or older age may not carry the same implications for the brain. That distinction matters because the developing brain remains in flux until around age 25, and the Centers for Disease Control and Prevention says cannabis can affect memory, learning, attention, decision-making, coordination, emotions and reaction time.

The public-health stakes are not abstract. In 2022, 30.7% of U.S. 12th graders reported cannabis use in the past year, and 6.3% reported daily use in the past 30 days. The CDC estimates that about 3 in 10 people who use cannabis have cannabis use disorder, with higher risk among people who start in youth or adolescence and use more often. The agency also estimated that 61.9 million people in the United States used cannabis in 2022, making it the most commonly used federally illegal drug in the country.

For teens, the question is not only whether cannabis is legal or common, but whether repeated use is landing on a brain still under construction. For frequent users, the key issue is cumulative exposure, especially when use climbs into the kind of heavy lifetime pattern measured in the JAMA Network Open study. For older adults, the unanswered question is whether the brain effects look the same after decades of development and aging, or whether the risks shift with timing, dose and product type.

That uncertainty is why the strongest findings now point to caution rather than certainty. A 2026 JAMA Internal Medicine review said evidence is not sufficient to support cannabis for treating mental health conditions and warned that THC-predominant products may worsen mania and psychotic symptoms in vulnerable people. The clearest takeaway is not that cannabis always damages the brain, but that the timing of use, the amount used and the concentration of THC can change the risk picture, and policy has to catch up to that nuance.